Company intelligence / Profile preview

Covis Pharma Holdings

Zug, Zug, Switzerland

Ownership: Private
Employees: ~800
Development stage: Other

Overview

Covis Pharma markets a broad portfolio of branded and generic drugs, primarily for respiratory, cardiovascular, CNS, and hematology indications, with most programs already approved and marketed globally in over 50 countries. Key products include inhaled therapies for asthma and COPD, injectables for anemia and cardiovascular diseases, and generics for chronic conditions.

Therapeutic areas: NephrologyWomen's HealthOtherCardiovascularPulmonologyGastroenterology
Modalities: Small moleculeBiologicCombination drugs
Industry: Biotech

Partnerships

Novartis (distribution agreements for Seebri Breezhaler and Ultibro Breezhaler in Canada)AstraZeneca (product acquisitions, such as Alvesco, Eklira, Duaklir)

Beyond the preview

Go deeper on Covis Pharma Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Covis Pharma Holdings.

Explore the full profile